Skip to main content
. 2022 Mar 7;16(3):e0010167. doi: 10.1371/journal.pntd.0010167

Fig 2. Patient Seroreactivity by Antigen.

Fig 2

The breadth of participant seroreactivity against ebolaviruses in the 36 reactive samples is illustrated. None of these individuals reported exposure to confirmed or probable EVD cases. The samples were characterized by the interpolation of the IgG concentration (Titer) divided by the EC50 of Adimab-15878 for the plate. They were further classified into separate groups by the level of the Titer/EC50 ratio: 1<2 for Weak Reactivity, 2≤10 for Moderate Reactivity, and 10+ for Strong Reactivity. Four samples were strongly reactive: 3 EBOV GPe (Titer/EC50: 86 (HCW 49), 16 (HCW 168), 16 (HCW 229)) and 1 SUDV GPΔMuc (Titer/EC50: 30 (HCW 29)).